ArticlebioRxiv : the preprint server for biology2026
A Chromatin Biology Assessment of AlphaFold3.
Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Biomolecular structure prediction tools such as AlphaFold have achieved remarkable success in predicting structures of single proteins and multiprotein complexes. AlphaFold3 now incorporates the capability to model complexes containing nucleic acids and chemically modified side chains. Investigators can now predict structures of proteins bound to chromatin, where interactions with nucleosomal DNA and histone post-translational modifications converge to control genome function. To evaluate its robustness in modeling chromatin complexes, we benchmarked AlphaFold3 on 115 structures containing nucleosomes whose coordinates were released by the Protein Data Bank after the training set cutoff date. We find that AlphaFold3 excels at predicting histone-driven interactions and accurately models complexes that deposit and recognize post-translational modifications. By contrast, AlphaFold3 struggles to predict structures of chromatin factors that primarily engage nucleosomal DNA, notably transcription factors and chromatin remodelers. Finally, we show that AlphaFold3 can faithfully recapitulate known post-translational modification recognition patterns, matching experimentally determined specificity profiles. This assessment of the capabilities and limitations of AF3 in chromatin structural biology provides a roadmap for its effective application to studies of chromatin regulation and PTM readout, while identifying key areas for future algorithmic refinement.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.